NCT04270552View on ClinicalTrials.gov

Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis

PHASE3CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 22, 2018

Primary Completion Date

July 20, 2018

Study Completion Date

August 12, 2018

Conditions
Allergic Rhinitis
Interventions
DRUG

Ismigen

Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.

DRUG

Placebo

Matched tablets without any active substance.

Trial Locations (1)

20-093

Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Lublin

All Listed Sponsors
lead

Medical University of Lublin

OTHER

NCT04270552 - Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis | Biotech Hunter | Biotech Hunter